The First Case of Coil Embolization for Left Gastric Vein Aneurysm with Liver Cirrhosis: A Case Report and Review of the Literature

Seiya Kato¹, Ryotaro Sakamori¹, Ryoko Yamada¹, Kazuhiro Murai¹, Teppei Yoshioka¹, Yuki Tahata¹, Minoru Shigekawa¹, Takahiro Kodama¹, Hayato Hikita¹, Hidenari Hongyo², Yusuke Ono², Hiroki Higashihara², Tomohide Tatsumi¹ and Tetsuo Takehara¹

Abstract:
We herein report the first case of interventional radiology for a left gastric vein aneurysm with a gastrorenal shunt. The etiology of the aneurysm was considered secondary to portal hypertension and liver cirrhosis due to hepatitis B virus infection. As the aneurysm was asymptomatic but had a tendency to expand, we successfully performed coil embolization for the aneurysm through a gastrorenal shunt.

Key words: portal venous system aneurysms, interventional radiology, coil embolization

(Intern Med Advance Publication)
(DOI: 10.2169/internalmedicine.6565-20)

Introduction

Portal venous system aneurysms (PVSAs) are considered congenital or secondary to portal hypertension, chronic hepatic disease, trauma, pancreatitis, etc. (1). Among approximately 250 cases of PWSA, only 1 case of a left gastric vein aneurysm was reported (2). Although the need for treatment for PVSAs remains controversial, therapeutic intervention should be considered when aneurysms have symptoms or expansion and show the possibility of rupture, thrombosis or adjacent organ compression (3). Surgical procedures have been the standard treatment for PVSAs, but recently, several cases of successful interventional radiology, such as portal stent graft placement, have been reported.

We herein report the first case of interventional radiology for a left gastric vein aneurysm through a gastrorenal shunt.

Case Report

The patient gave her informed consent for the publication of the details of her case.

A 67-year-old woman with hepatitis B virus (HBV)-related liver cirrhosis, hyperammonemia and gastroesophageal varices was undergoing follow-up at our hospital. She had a history of hypophyseal adenoma, hypothyroidism and hyperlipidemia. She was taking entecavir, rifaximin, lactitol, levothyroxine and ezetimibe. She had undergone a follow-up examination every six months with ultrasonography before, and no aneurysm had been detected. Dynamic contrast-enhanced computed tomography (CT) performed for hepatocellular carcinoma surveillance revealed splenomegaly, a gastrorenal shunt, and a saccular left gastric vein aneurysm 22 mm in diameter (Fig. 1A, B). Follow-up CT after 10 months showed enlargement of the aneurysm (32 mm in diameter) with no ascites or portal thrombosis (Fig. 1C, D, 2). Laboratory studies showed anemia (Table 1). The Child-Pugh class was B. The aneurysm was asymptomatic but showed an expanding tendency.

Coil embolization for the saccular aneurysm was performed to prevent rupture. An 8-Fr sheath (ASATO; Medikit, Co., Ltd., Tokyo, Japan) was inserted via the right femoral vein with local anesthesia. At first, a 4-Fr catheter (Cerulean G; Medikit, Co., Ltd., Tokyo, Japan) was inserted...
and placed retrogradely through the tortuous gastrorenal shunt to the left gastric vein with a 0.035-inch guide wire (Radifocus; Terumo Corporation, Tokyo, Japan). A 2.7-Fr coaxial microcatheter (PX SLIM; Penumbra, Inc., Alameda, CA, USA) was then advanced into the saccular aneurysm with a 0.025-inch guidewire (Radifocus; Terumo Corporation) and a 0.016-inch micro guidewire (Run & Run; Piolax, Inc., Kanagawa, Japan) (Fig. 3A).

We performed coil packing of the aneurysm, such as via the coil embolization technique, to prevent embolization of the left gastric vein, which was the main collateral vein with portal hypertension. The types and numbers of coils used were as follows: standard Ruby coils, 3 at 36 mm x 60 cm, 3 at 28 mm x 60 cm, 3 at 24 mm x 60 cm, 1 at 14 mm x 60 cm and 2 at 12 mm x 60 cm; soft Ruby coils, 1 at 10 mm x 35 cm and 2 at 8 mm x 35 cm; and Penumbra occlusion device (POD) packing coils, 2 at 30 cm and 1 at 15 cm (Penumbra, Inc.). After coil embolization, venography from the left gastric vein showed the disappearance of blood flow to the aneurysm. Finally, we punctured the right femoral artery and inserted a 4-Fr sheath (Medikit, Co., Ltd.). Arteriography from the superior mesenteric artery and celiac artery was performed (Fig. 3B, C). We confirmed the disappearance of the blood flow from inside the aneurysm and the preservation of the blood flow to the portal vein and left gastric vein.

Contrast-enhanced CT performed eight days after coil embolization showed neither blood flow to the aneurysm nor portal thrombosis (Fig. 3D, E, F). The patient was discharged from the hospital 12 days after treatment. After discharge, she had no symptoms, and her liver function did not worsen. The serum NH3 value at 4 months after treatment was 89 μg/dL, and no symptoms of hepatic encephalopathy

Figure 1. A, B) Dynamic contrast-enhanced computed tomography (CT) showing splenomegaly, a gastrorenal shunt and a saccular left gastric vein aneurysm (a: arrow). C, D) Follow-up CT after 10 months showing enlargement of the aneurysm (c: arrow).

Figure 2. Multidetector computed tomography images showing the location of a left gastric vein aneurysm. A) Relative location of a left gastric vein aneurysm (arrow) in the portal venous system. Yellow indicates the inferior vena cava and left renal vein. Green indicates the main portal vein, splenic vein and superior mesenteric vein. Purple indicates the left gastric vein aneurysm (arrow) and gastrorenal shunt. B) Ventral side of the left gastric vein aneurysm (arrow) and gastrorenal shunt. C) Dorsal side of the left gastric vein aneurysm (arrow) and gastrorenal shunt.
Table 1. Laboratory Data.

| WBC     | 6.66 x10^9/μL | LDH  | 149 U/L | Alb  | 3.3 g/dL |
|---------|----------------|------|---------|------|----------|
| RBC     | 3.42 x10^12/μL | T-Bil| 1.4 mg/dL | CRP  | 0.48 mg/dL |
| Hb      | 10.3 g/dL      | D-Bil| 0.6 mg/dL | NH3  | 88 μg/dL  |
| Ht      | 30.9 %         | γ-GTP| 33 U/L  | Zn   | 85 μg/dL  |
| PIt     | 14.5 x10^4/μL  | Amy  | 89 IU/L | AFP  | 6 ng/mL  |
| PT      | 62 %           | BUN  | 11 mg/dL | DCP  | 35 mAI/mL |
| PT-INR  | 1.29           | Cr   | 0.64 mg/dL | HBsAg| 175.0 U/mL |
| APTT    | 32 sec         | Na   | 141 mEq/L | HBV DNA | N.D. |
| D-dimer | 1.21 μg/mL     | K    | 3.4 mEq/L | Anti-HCV | N.D. |
| AST     | 20 U/L         | Cl   | 105 mEq/L | FIB-4 | index 3.38 |
| ALT     | 8 U/L          | TP   | 7.6 g/dL | ARFI | 2.41±0.31 m/s |

WBC: white blood cell, RBC: red blood cell, Hb: hemoglobin, Ht: hematocrit, PIt: platelet, PT: prothrombin time, PT-INR: prothrombin time international normalized ratio, APTT: activated partial thromboplastin time, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactic acid dehydrogenase, T-Bil: total bilirubin, D-Bil: direct bilirubin, γ-GTP: γ-glutamyl transpeptidase, BUN: blood urea nitrogen, Cr: creatinine, TP: total protein, Alb: albumin, CRP: C-reactive protein, AFP: α-fetoprotein, DCP: des-γ-carboxy prothrombin, HBsAg: hepatitis B surface antigen, HBV DNA: hepatitis B virus deoxyribonucleic acid, Anti-HCV: antibodies against hepatitis C virus, N.D.: not detected, FIB-4 index: fibrosis-4 index, ARFI: Acoustic Radiation Force Impulse.

Figure 3. Through a gastrorenal shunt, we performed coil embolization of the left gastric vein aneurysm (arrow). After treatment of the aneurysm, we checked the blood flow of the portal venous system, including the left gastric vein. A) Portography before treatment. B) Arteriopography of the superior mesenteric artery after treatment. C) Arteriopography of the celiac artery after treatment. D) Non-contrast-enhanced computed tomography (CT). E) Dynamic contrast-enhanced CT eight days after treatment, showing neither blood flow in the aneurysm (arrow) nor portal vein thrombosis. F) Remaining blood flow of the gastrorenal shunt (arrow).

Discussion

This is the first case of interventional radiology for a left gastric vein aneurysm through a gastrorenal shunt. In addition, we performed coil embolization for PVSA, which has never been reported, although several cases of portal stent graft placement for PVSAs have been reported.
The portal venous system is a group of veins involved in drainage of the capillary beds of the gastrointestinal tract and spleen into the capillary bed of the liver, including the main portal vein, splenic vein, superior mesenteric vein, inferior mesenteric vein and left gastric vein. PVSAs are rare, and left gastric vein aneurysms are extremely rare. Koc et al. reported that the prevalence of PVSAs was 0.43% among 4,186 patients who underwent routine abdominal CT (4). The most common locations of PVSAs are the main portal vein and the confluence of the superior mesenteric vein and splenic vein (5). Although approximately 250 cases of PVSA have been reported, only 1 case of a left gastric vein aneurysm has previously reported (by Matsutani et al.) (2).

The etiology of PVSAs is considered to be congenital or acquired. Congenital causes of PVSAs are considered to include abnormal weakness of the vein wall, incomplete regression of the distal right primitive vitelline vein or branching variants of the portal vein (6, 7). Acquired causes are considered to include portal hypertension, chronic hepatic disease, thrombophilia, trauma, inflammation such as pancreatitis and complications of abdominal surgery (1, 4). Portal hypertension and liver cirrhosis are the main acquired causes, reported in approximately 30% of patients with PVSAs. Recently, the number of patients with PVSAs but without portal hypertension or chronic hepatic disease has increased because of the prevalence of noninvasive medical imaging techniques, such as ultrasound, CT, and magnetic resonance imaging (8, 9). Our patient had liver cirrhosis due to HBV infection, considering the fibrosis-4 (FIB-4) index and acoustic radiation force impulse (ARFI) values (Table 1), and had portal hypertension, considering the existence of splenomegaly, a gastrorenal shunt and gastroesophageal varices. The aneurysm, which was located in a left gastric vein with a gastrorenal shunt, was considered to have been caused by portal hypertension and liver cirrhosis.

The need to treat PVSAs is still controversial. Small aneurysms are usually asymptomatic, while large aneurysms seem to cause symptoms or complications, such as thrombosis, rupture or duodenal or biliary obstruction (10-13). Syroeras et al. reported in a systematic review that thrombosis occurred in 13.6%, rupture in 2.2% and adjacent organ compression in 2.2% of 191 cases of PVSA (1). In addition, in 94% of the 53 cases that were followed up, the aneurysm diameter remained stable, and no complications occurred during follow-up. In our case, since the left gastric vein aneurysm was asymptomatic but showed an expanding ten-

Figure 4. A, B) Esophagogastroduodenoscopy showing gastroesophageal varices (arrow) before treatment. C, D) Esophagogastroduodenoscopy showing gastroesophageal varices (arrow) four months after treatment.
dency, we performed treatment, considering the risk of rupture.

Surgical procedures, including aneurysmorrhaphy, aneurysmectomy, splenectomy, splenorenal shunt surgery and distal pancreatectomy, have been the standard treatments for PVSAs (1, 14), and more than 30 cases of surgically treated PVSAs have been reported. However, patients with liver cirrhosis, especially decompensated cirrhosis, such as our patient, have increased rates of perioperative mortality. Recently, several cases of successful interventional radiology for PVSAs, such as portal stent graft placement, have been reported (Table 2), including the treatment of a traumatic splenic vein aneurysm through a transsplenic approach using a portal stent (15) and a splenic vein aneurysm through a transhepatic approach (16). In these two cases, antplatelet therapy was started after endovascular treatment to prevent portal thrombosis. In our case, the left gastric vein ended at the splenic vein, and the aneurysm was located immediately above the junction of the left gastric vein and the splenic vein. Therefore, we applied coil embolization through a gastrorenal shunt instead of an endovascular stent graft due to the vascular anatomy. We did not start antplatelet therapy because a stent graft, which can cause clot formation, was not used.

Generally, balloon-occluded retrograde transvenous obliteration (BRTO) is effective for managing solitary gastric varices or recurrent hepatic encephalopathy with a portosystemic shunt (17, 18). Furthermore, there are some data showing that BRTO improves the liver function via an increase in the portal venous flow volume after shunt occlusion (17, 19). Some previous studies have reported that the predictive factor for improvement in the liver function by BRTO was a reduced liver stiffness (20, 21). If we perform BRTO for gastric varices, we need to occlude the gastrorenal shunt, including the left gastric vein aneurysm. However, because the gastric varices form was F1 and her hepatic encephalopathy was controlled by medication, such as rifaximin and lactitol, we decided that BRTO for gastric varices was not necessary at this time. Therefore, we selected coil embolization for the aneurysm. Preservation of the blood flow of the shunt will allow us to perform BRTO through this gastrorenal shunt should the gastric varices grow larger or hepatic encephalopathy become uncontrolled.

In conclusion, to our knowledge, this is the first report of using coil embolization to treat a PVSA. Further studies are needed to evaluate the efficacy of interventional radiology for treating PVSAs.

The authors state that they have no Conflict of Interest (COI).

References

1. Sfyroeras GS, Antoniou GA, Drakou AA, et al. Visceral venous aneurysms: clinical presentation, natural history and their management: a systematic review. Eur J Vasc Endovasc Surg 38: 498-505, 2009.
2. Matsutani S, Mizumoto H. Aneurysm of the left gastric vein in a patient with portal hypertension. J Med Ultrason 35: 141-143, 2008.
3. Calligaro KD, Ahmad S, Dadora R, et al. Venous aneurysms: Surgical indications and review of the literature. Surgery 117: 1-6, 1995.
4. Koc Z, Oguzzurt L, Ulasan S. Portal venous system aneurysms: imaging, clinical findings, and a possible new etiologic factor. Am J Roentgenol 189: 1023-1030, 2007.
5. Lopez-Machado E, Mallorquin-Jimenez F, Medina-Benitez A, et al. Aneurysm of the portal venous system: ultrasonography and CT findings. Eur J Radiol 26: 210-214, 1998.
6. Gallego C, Velasco M, Marcuello P, et al. Congenital and acquired anomalies of the portal venous system. Radiographics 22: 141-159, 2002.
7. Yang DM, Yoon MH, Kim HS, et al. Portal vein aneurysm of the umbilical portion: imaging features and the relationship with portal vein anomalies. Abdom Imaging 28: 62-67, 2003.
8. Dognini L, Carreri AL, Moscatelli G. Aneurysm of the portal vein: ultrasound and computed tomography identification. J Clin Ultrasound 19: 178-182, 1991.
9. Ohnami Y, Ishida H, Konno K, et al. Portal vein aneurysm: report of six cases and review of the literature. Abdom Imaging 22: 281-286, 1997.
10. Wolff M, Schaefer N, Schmidt J, et al. Thrombosis of a large portal vein aneurysm: treatment by thrombectomy, aneurysmorrhaphy, and portocaval shunt. J Gastrointest Surg 10: 128-131, 2006.
11. Barzilai R, Kleckner MS. Hemocholecest following ruptured aneurysm of portal vein; report of a case. AMA Arch Surg 72: 725-727, 1956.
12. Shimoda M, Kubota K, Sakuma A, et al. Intra-abdominal Hemorrhage Due to Rupture of a Splenic Vein Aneurysm: A Case Report. J Gastrointest Surg 7: 683-686, 2003.
13. Lall C, Verma S, Gulati R, et al. Portal vein aneurysm presenting with obstructive jaundice. J Clin Imaging Sci 2: 54, 2012.
14. Cho SW, Marsh JW, Fontes PA, et al. Extrahepatic portal vein aneurysm—report of six patients and review of the literature. J Gastrointest Surg 12: 145-152, 2008.
15. Kwon OS, Sul YH, Kim JS, et al. Endovascular stent graft for traumatic splenic vein aneurysm via percutaneous transsplenic access. Ann Surg Treat Res 91: 56-58, 2016.

Table 2. Interventional Radiology for Portal Venous System Aneurysms.

| Author       | Year | Age | Gender | Size of Aneurysm (mm) | Location of Aneurysm | Etiology               | Symptom / Complication   | Treatment               |
|--------------|------|-----|--------|-----------------------|----------------------|------------------------|--------------------------|-------------------------|
| Kwon OS, et al.15 | 2016 | 56  | male   | 22                    | splenic vein         | trauma                 | epigastric pain / rupture | portal stent graft       |
| Juscaferesa LC, et al.16 | 2019 | 77  | female | 45                    | splenic vein         | incidental finding after pancreatitis | None                    | portal stent graft       |
| Our case     | -    | 67  | female | 32                    | left gastric vein    | liver cirrhosis        | None                     | coil embolization        |

Table 2. Interventional Radiology for Portal Venous System Aneurysms.
16. Juscafresa LC, Alfaro MP, Grochowicz L, et al. Endovascular treatment of a splenic vein aneurysm through a transhepatic approach. Diagn Interv Radiol 25: 166-168, 2019.

17. Kato T, Uematsu T, Nishigaki Y, et al. Therapeutic effect of balloon-occluded retrograde transvenous obliteration on porto-systemic encephalopathy in patients with liver cirrhosis. Intern Med 40: 688-691, 2001.

18. Choudhary NS, Baijal SS, Saigal S, et al. Results of Portosystemic Shunt Embolization in Selected Patients with Cirrhosis and Recurrent Hepatic Encephalopathy. J Clin Exp Hepatol 7: 300-304, 2017.

19. Miyamoto Y, Oho K, Kumamoto M, et al. Balloon-occluded retrograde transvenous obliteration improves liver function in patients with cirrhosis and portal hypertension. J Gastroenterol Hepatol 18: 934-942, 2003.

20. Yamamoto A, Nishida N, Morikawa H, et al. Prediction for Improvement of Liver Function after Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices to Manage Portosystemic Shunt Syndrome. J Vasc Interv Radiol 27: 1160-1167, 2016.

21. Ishikawa T, Sasaki R, Nishimura T, et al. Liver stiffness measured by transient elastography as predictor of prognoses following portosystemic shunt occlusion. J Gastroenterol Hepatol 34: 215-223, 2019.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).